Analog insulin detemir for patients with type 1 and type 2 diabetes: A review

Diabetes, Metabolic Syndrome and Obesity

Volumn 2, Issue , 2009, Pages 31-36

  Peterson, Gregory E ^a  

^a DES MOINES UNIVERSITY   (United States)

Author keywords

Insulin analogs; Insulin detemir; Type 1 diabetes; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT;

ADD ON THERAPY; CLINICAL TRIAL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 77953425953     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/dmsott.s3401     Document Type: Review

References (32)

1. Peterson GE. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Curr Med Res Opin. 2006;22:2613-2619.
2. The Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications. Diabetes. 1996;45:1289-1298.
3. Reichard O, et al. The effect of long-term intensified insulin treatment of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329:304-309.
4. Wang PH, et al. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet. 1993;341:1306-1309.
5. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes. 1997;46:271-286.
6. Nathan DM, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25): 2643-2653.
7. Stratton IM, et al. Association with glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
8. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. The Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/ EDIC) Study Research Group. N Engl J Med. 2005;353:2643-2653.
9. Gæde P. Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. Diabetes. 2004;53:S39-S47.
10. Bloomgarden ZT. Glycemic control in diabetes: a tale of three studies. Diabetes Care. 2008;31:1913-1919.
11. Wright A. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330-336.
12. Dluhy RG. Intensive Glycemic Control in the ACCORD and ADVANCE Trials. N Engl J Med. 2008;358:2630-2633.
13. Hirsch IB. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complicat. 2005;19: 178-181.
14. Unger J. Reducing oxidative stress in patients with type 2 diabetes mellitus: A primary care call to action. Insulin. 2008;3(3):176-184.
15. Rendell MS. Targeting postprandial hyperglycemia. Metabolism. 2006;55:1263-1281.
16. Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Pediatr Diabetes. 2008;9:382-387.
17. Danne T. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type1 diabetes. Diabetes Care. 2003;26:3087-3092.
18. Le Floch JP, et al. A comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT). Diabetes Care. 2009;32:32-37.
19. Home P, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type I diabetes: a randomized clinical trial. Diabetes Care. 2004;27:1081-1087.
20. Russell-Jones D, et al. Effects of QD insulin detemir or neutral protamine hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal- bolus regimen. Clin Ther. 2004;26:724-736.
21. Robertson K, et al. Benefits of insulin detemir over NPH insulin in children and adolescents with type 1 diabetes: lower and more predictable fasting plasma glucose and lower risk of nocturnal hypoglycemia. Diabetes. 2004;53(Suppl 2):A144.
22. Hermansen K, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes. Diabetologia. 2004;47:622-629.
23. Kolendorf K, et al. Insulin detemir is associated with lower risk of hypoglycemia than NPH insulin in people with type 1 diabetes. Diabetes. 2004;53 Suppl 1:A130.
24. Pieber TR. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir versus morning plus bedtime NPH insulin. Diabetic Med. 2005;22:850-857.
25. Haak T, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7:56-64.
26. Raslova K, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for Type 2 diabetes. Diabetes Res Clin Pract. 2004;66:193-201.
27. Hermansen K, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose- lowering drugs in insulin-naïve people with Type 2 diabetes. Diabetes Care. 2006;29:1269-1274.
28. Meneghini LF, Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab. 2007;9:418-427.
29. Meneghini L. Efficacy and safety of insulin detemir in a large cohort of patients with type 2 diabetes suing a simplified self-adjusted dosing guideline - results of the PREDICTIVE 303 study. Program and abstracts of the 67th Scientific Sessions of the American Diabetes Association; June 22-26, 2007;Chicago, Illinois. Abstract 197-OR.
30. Rosenstock J. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when added to glucose-lowering drugs in insulin-naïve people with Type 2 diabetes. Diabetologia. 2008;51:408-416.
31. Fajardo Montañana C, Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabet Med. 2008;25(8):916-923.
32. Peterson GE. Insulin detemir in type 1 and type 2 diabetes [abstract]. Ehrlich II World Congress, Nurenberg, Germany, October 2008.